Status:
UNKNOWN
Cannabinoid Supplementation on Vascular and Cognitive Function
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
Lexaria Bioscience Corp.
Conditions:
Diet Modification
Eligibility:
All Genders
18-75 years
Phase:
EARLY_PHASE1
Brief Summary
Cannabidiol (CBD) is a bioactive cannabinoid compound in marijuana (cannabis sativa), but unlike Δ9 tetrahydrocannabinol (THC), lacks the psychoactivity effect of THC. Available evidence suggests that...
Eligibility Criteria
Inclusion
- non-smoking
- non-obese
- between the ages of 18-30 \& 60-75 years
- have no history of cardiopulmonary, liver, gastrointestinal, kidney or cerebrovascular disease.
Exclusion
- are obese
- are taking prescription drugs or over-the-counter supplements that influence cardiovascular or nitric oxide metabolism
- have a history of smoking
- have history of cardiovascular, respiratory (including asthma) or neurological disease
- have known intolerance to ginseng or ginkgo herbals
- have kidney, gastrointestinal or liver disease
- have epilepsy
- have diabetes
- are pregnant or breast feeding
- do not speak English as first language
- a student in the University of British Columbia (UBC) Okanagan Centre for Heart, Lung and Vascular Health
- medical or recreational use of cannabis
- clinically diagnosed anxiety or depression
- history of opioid use
- unwilling or unable to execute the informed consent documentation
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2021
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03295903
Start Date
January 1 2018
End Date
October 1 2021
Last Update
October 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of British Columbia
Kelowna, Ontario, Canada, V1V 1V7